Bank of America started coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report published on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $38.00 price objective on the stock.
Separately, Evercore ISI initiated coverage on shares of Metsera in a report on Tuesday. They issued an “outperform” rating for the company.
Read Our Latest Stock Analysis on MTSR
Metsera Trading Down 8.3 %
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- Best Stocks Under $5.00
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- 3 Monster Growth Stocks to Buy Now
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What is Short Interest? How to Use It
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
